Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)

NCT: NCT07675109 · RECRUITING

NCT IDNCT07675109
StatusRECRUITING
Start Date2026-06-08
Completion2027-06
SponsorNoctrix Health, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.

Frequently Asked Questions

What is Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)?

Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) is a clinical trial registered under NCT07675109. Current status: RECRUITING.

What is the status of NCT07675109?

The current status of NCT07675109 (Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)) is: RECRUITING.

When did Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) start?

Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) started on 2026-06-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑